Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity

Amblyomin-X, a Kunitz-type protease inhibitor, is a recombinant protein that selectively induces apoptosis in tumor cells and promotes tumor reduction in vivo in melanoma animal models. Furthermore, Amblyomin-X was able to drastically reduce lung metastasis in a mice orthotopic kidney tumor model. Due to its antitumor activity, Amblyomin-X potential to become a new drug is currently under investigation, therefore the aim of the present study was to perform preclinical assays to evaluate Amblyomin-X toxicity in healthy mice. Exploratory toxicity assays have shown that treatment with 512?mg/kg of Amblyomin-X lead to animal mortality, therefore two groups of treatment were evaluated in the present work: in the acute toxicity assay, animals were injected once with doses ranging from 4 to 256?mg/kg of Amblyomin-X, while in the subacute toxicity assay, animals were injected with 0.25, 0.57 and 1?mg/kg of Amblyomin-X daily, during 28 days. Following this treatment regimens, Amblyomin-X did not cause any mortality; moreover, toxicity signs were discrete, reversible and observed only at the higher doses, thus establishing a safety profile for administration in mice, which can be further used to determine the dose translation of this novel drug candidate for treatment in other species.
Keywords
Amblyomin-X;  Kunitz-type inhibitor;  Toxicity;  Preclinical

metadata.dc.contributor
Document type
Article
Source
Maria DA, Will SEAL, Bosch RV, Souza JG, Sciani JM, Goldfeder MB, et al. Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity. Toxicol. Rep.. 2019;6:51-63. doi:10.1016/j.toxrep.2018.11.014.
Appears in Collections:
Metrics
Rights
Open Access
URL
URI

Show full item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.